Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Orionis Biosciences, a privately held, clinical-stage life sciences company focused on the rational discovery and development of drug modalities with induced proximity mode of action, today announced ...

Visa , a global leader in digital payments, announced the general availability of its innovative product, Visa AR Manager, in the United States. Visa AR Manager is designed to grow and maintain ...

Orionis will design molecular glues for targets chosen by Roche’s Genentech unit, with the latter responsible for taking over responsibility for any resulting candidates from the late ...

Genentech for its part has not been shy in dealmaking lately ... That followed a September 2023 deal with Orionis worth up to $2 billion for molecular glue degraders in cancer and neurodegeneration, ...